Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET

Company Participants

Alina Venezia - Director of Investor Relations
Sheldon Koenig - President and Chief Executive Officer
Ben Halladay - Chief Financial Officer
Eric Warren - Chief Commercial Officer
Betty Swartz - Chief Business Officer

Conference Call Participants

Dennis Ding - Jefferies
Serge Belanger - Needham
Cameron Bozdog - Bank of America

Operator

Ladies and gentlemen. Thank you for standing by. Welcome to Esperion’s Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the presentation there will be a question-and-answer session. Please be advised that today's conference call may be recorded.

I would now like to hand the conference over to Alina Venezia, Director of Investor Relations. Please go ahead.

Alina Venezia

Thank you, Operator. Good morning and welcome to Esperion’s second quarter 2024 earnings conference call. With us today are Sheldon Koenig, President and CEO, and Ben Halladay, CFO. Other members of the executive team will be available for Q&A following our prepared remarks.

We issued a press release earlier this morning detailing the content of today's call. A copy can be found on our investor page of our website together with a copy of the presentation that we will also be referencing. I wanted to remind callers that information discussed on the call today is covered under the Safe Harbor provision of the Private Securities Litigation Reform Act.

I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statement due to the risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and in our SEC filings. The content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, August 12, 2024. We undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call and webcast.

As a reminder, this conference call and webcast are being recorded and archived. We will begin the call with prepared remarks and then open the line for your questions.

I'll now turn the call over to Sheldon.

Sheldon Koenig

Thank you, Alina, and good morning, everyone. Thank you for joining us today to review the meaningful progress we have made during the second quarter and to review our plans moving forward to continue to cement NEXLETOL and NEXLIZET as cornerstone therapies in reducing cardiovascular risk.